Billionaire investor Warren Buffett’s adage about the stock market emphasizes the value of patience, a principle particularly relevant in today’s healthcare sector, where GLP-1 weight-loss drugs are generating significant investor interest. Eli Lilly (LLY) stands out as a robust player, boasting multiple approved GLP-1 products and impressive financials, including a 45% sales increase in 2025, totaling over $65 billion. Its recent FDA approval of the weight loss pill Foundayo further solidifies its growth trajectory, making it a solid choice for risk-averse investors.

In contrast, Viking Therapeutics (VKTX) presents a riskier yet potentially rewarding opportunity with its GLP-1 drug, VK2735, which is currently in phase 3 trials. While the company lacks revenue, its promising clinical trial results could lead to substantial upside if the drug gains approval. The market cap difference—$4 billion for Viking versus $830 billion for Eli Lilly—highlights the risk-reward dynamic at play.

For investors weighing options in the healthcare sector, Eli Lilly offers stability, while Viking Therapeutics could yield higher returns if VK2735 successfully navigates the approval process. The choice hinges on individual risk tolerance and investment strategy.

Source: fool.com